Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Proceedings of the National Academy of Sciences of the United States of America
|
March 31, 1999
Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier
V V Rao, J L Dahlheimer, M E Bardgett, et al.
Biochemical Pharmacology
|
February 29, 2000
Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity
R A Finch, M Liu, S P Grill, et al.
Journal of Applied Toxicology : JAT
|
November 5, 1999
Phase III interlaboratory study of FETAX. Part 3. FETAX validation using 12 compounds with and without an exogenous metabolic activation system
J A Bantle, R A Finch, D J Fort, et al.
Journal of Medicinal Chemistry
|
January 1, 1990
Synthesis and in vivo antitumor activity of 2-amino-9H-purine-6-sulfenamide, -sulfinamide, and -sulfonamide and related purine ribonucleosides
G R Revankar, N B Hanna, N Imamura, et al.
Biochemical Pharmacology
|
October 15, 1989
Inhibition of phosphoribosylpyrophosphate synthetase by 4-methoxy-(MRPP) and 4-amino-8-(D-ribofuranosylamino) pyrimido[5,4-d]pyrimidine (ARPP)
L D Nord, R C Willis, T S Breen, et al.
Journal of Applied Toxicology : JAT
|
May 1, 1994
Initial interlaboratory validation study of FETAX: phase I testing
J A Bantle, D T Burton, D A Dawson, et al.
Journal of Applied Toxicology : JAT
|
November 1, 1996
FETAX interlaboratory validation study: phase III--Part 1 testing
J A Bantle, R A Finch, D T Burton, et al.
Environmental Health Perspectives
|
March 25, 1999
Animals as sentinels of human health hazards of environmental chemicals
W H van der Schalie, H S Gardner, J A Bantle, et al.
Drug and Chemical Toxicology
|
April 8, 1998
Phase III interlaboratory study of FETAX, Part 2: interlaboratory validation of an exogenous metabolic activation system for frog embryo teratogenesis assay--Xenopus (FETAX)
D J Fort, E L Stover, J A Bantle, et al.
Cold Spring Harbor Symposia on Quantitative Biology
|
September 2, 2004
High-throughput mouse knockouts provide a functional analysis of the genome
C J Friddle, A Abuin, R Ramirez-Solis, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Proceedings of the National Academy of Sciences of the United States of America
|
March 31, 1999
Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier
V V Rao, J L Dahlheimer, M E Bardgett, et al.
Biochemical Pharmacology
|
February 29, 2000
Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity
R A Finch, M Liu, S P Grill, et al.
Journal of Applied Toxicology : JAT
|
November 5, 1999
Phase III interlaboratory study of FETAX. Part 3. FETAX validation using 12 compounds with and without an exogenous metabolic activation system
J A Bantle, R A Finch, D J Fort, et al.
Journal of Medicinal Chemistry
|
January 1, 1990
Synthesis and in vivo antitumor activity of 2-amino-9H-purine-6-sulfenamide, -sulfinamide, and -sulfonamide and related purine ribonucleosides
G R Revankar, N B Hanna, N Imamura, et al.
Biochemical Pharmacology
|
October 15, 1989
Inhibition of phosphoribosylpyrophosphate synthetase by 4-methoxy-(MRPP) and 4-amino-8-(D-ribofuranosylamino) pyrimido[5,4-d]pyrimidine (ARPP)
L D Nord, R C Willis, T S Breen, et al.
Journal of Applied Toxicology : JAT
|
May 1, 1994
Initial interlaboratory validation study of FETAX: phase I testing
J A Bantle, D T Burton, D A Dawson, et al.
Journal of Applied Toxicology : JAT
|
November 1, 1996
FETAX interlaboratory validation study: phase III--Part 1 testing
J A Bantle, R A Finch, D T Burton, et al.
Environmental Health Perspectives
|
March 25, 1999
Animals as sentinels of human health hazards of environmental chemicals
W H van der Schalie, H S Gardner, J A Bantle, et al.
Drug and Chemical Toxicology
|
April 8, 1998
Phase III interlaboratory study of FETAX, Part 2: interlaboratory validation of an exogenous metabolic activation system for frog embryo teratogenesis assay--Xenopus (FETAX)
D J Fort, E L Stover, J A Bantle, et al.
Cold Spring Harbor Symposia on Quantitative Biology
|
September 2, 2004
High-throughput mouse knockouts provide a functional analysis of the genome
C J Friddle, A Abuin, R Ramirez-Solis, et al.
Page
of 5